Berkshire Hathaway Reveals New Stakes in Delta Air Lines and Macy’s Under Greg Abel 
SpaceX Shareholders Approve 5-for-1 Stock Split Ahead of Potential IPO 
CXMT Forecasts Record Revenue Growth as Global DRAM Prices Surge 
Samsung Strike Talks Resume as South Korea Weighs Emergency Action 
Sonova Beats Profit Forecasts Despite Cochlear Implant Weakness 
Nvidia’s China AI Chip Sales Remain Frozen Despite U.S. Approval 
Asia-Pacific Banks Brace for Rising Credit Risks Amid Iran Conflict 
DOJ May Drop Gautam Adani Fraud Charges Amid $10 Billion U.S. Investment Plan 
TSMC Stake Sale Sends Vanguard Semiconductor Shares Lower 
Samsung Faces Major Strike Threat as Union Restarts Pay Talks 
Anthropic Nears $30 Billion Funding Round at $900 Billion Valuation 
Elon Musk’s China Influence Faces New Challenges Amid Rising EV Competition 
YouTube and Snap Settle School District Mental Health Lawsuit Ahead of Major Social Media Trial 
US-China Trade Talks Sideline Chip Export Controls as Nvidia China Sales Draw Attention 
Alibaba Stock Surges After Strong Q4 Earnings Boosted by AI and Cloud Growth 
Alphabet Raises Record $3.6 Billion in Yen Bonds to Support AI Expansion 
BERKELEY, Calif., Sept. 22, 2016 -- Aduro Biotech, Inc. (NASDAQ:ADRO) today announced that Stephen T. Isaacs, chairman, president and chief executive officer of Aduro, will present at the LEERINK Partners Roundtable Series: Rare Disease & Immuno-Oncology in New York, NY on Thursday, September 29, 2016, at 8:00 am Eastern Time.
To access the live webcast and subsequent archived recording of this and the company’s other presentations, please visit Aduro's website at www.aduro.com.
About Aduro
Aduro Biotech, Inc. is an immunotherapy company focused on the discovery, development and commercialization of therapies that transform the treatment of challenging diseases. Aduro's technology platforms, which are designed to harness the body's natural immune system, are being investigated in cancer indications and have the potential to expand into autoimmune and infectious diseases. Aduro's LADD technology platform is based on proprietary attenuated strains of Listeria that have been engineered to express tumor-associated antigens to induce specific and targeted immune responses. This platform is being developed as a treatment for multiple indications, including pancreatic, ovarian, lung and prostate cancers, mesothelioma and glioblastoma. Aduro's STING Pathway Activator platform is designed to activate the intracellular STING receptor, resulting in a potent tumor-specific immune response. ADU-S100 is the first STING Pathway Activator compound to enter the clinic and is currently being evaluated in a Phase 1 study in patients with cutaneously accessible metastatic solid tumors or lymphomas. Aduro’s B-select monoclonal antibody platform includes a number of immune modulating assets in research and preclinical development. Aduro is collaborating with leading global pharmaceutical companies to expand its products and technology platforms. For more information, please visit www.aduro.com.
Contact: Alexandra Santos Sr. Director, Corporate Affairs 510 809 9231 Media Contact: Angela Bitting 925 202 6211 [email protected]
